Alan Aboaf, MD
Internal Medicine · Centennial, CONPI 1003866393
Payments from drug & device makers
Across 181 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$483
- AstraZeneca$417
- Philips North America LLC$337
- Novo Nordisk$312
- GSK$206
- Exact Sciences$196
- plus $2K from 36 others
What the payments were for
- Speaking & faculty fees$150%
- Food & beverage$3,81899%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $483 |
| AstraZeneca | 20 | $417 |
| Philips North America LLC | 9 | $337 |
| Novo Nordisk | 16 | $312 |
| GSK | 10 | $206 |
| Exact Sciences | 10 | $196 |
| Abbott | 10 | $177 |
| Amgen(2 entities) | 6 | $134 |
| Lilly USA, LLC | 7 | $109 |
| Seqirus USA Inc | 4 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $94 |
| Merck | 5 | $93 |
| Edwards Lifesciences | 3 | $92 |
| Teva Pharmaceuticals USA, Inc. | 4 | $91 |
| Dexcom, Inc. | 4 | $80 |
| AbbVie | 3 | $75 |
| VBI Vaccine (delaware) Inc. | 2 | $69 |
| Boehringer Ingelheim | 3 | $67 |
| Idorsia Pharmaceuticals US Inc | 4 | $60 |
| BETA Bionics, Inc. | 2 | $57 |
| Gilead | 3 | $54 |
| Abiomed | 1 | $43 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| GE HealthCare | 2 | $40 |
| Lucid Diagnostics Inc. | 2 | $40 |
| Aimmune Therapeutics, Inc. | 2 | $39 |
| Cleerly, Inc. | 1 | $35 |
| Astellas Pharma US Inc | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Biogen | 1 | $23 |
| Novartis | 1 | $22 |
| Bioventus LLC | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Bayer | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Inogen, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Exeltis, USA Inc. | 1 | $15 |
| Mckesson Medical-surgical, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (5044) MCOT$134
How this compares
$3,851 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $118,908 |
| OzempicSemaglutide | 67 | $111,189 |
| MounjaroTirzepatide | 45 | $60,479 |
| TrulicityDulaglutide | 18 | $43,505 |
| XareltoRivaroxaban | 38 | $40,438 |
| JardianceEmpagliflozin | 24 | $39,012 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $33,152 |
| FarxigaDapagliflozin Propanediol | 16 | $23,996 |
| RybelsusSemaglutide | 11 | $22,739 |
| MyrbetriqMirabegron | 17 | $22,573 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $8,281 |
| Atorvastatin Calcium | 425 | $3,925 |
| Omeprazole | 137 | $3,844 |
| Levothyroxine Sodium | 328 | $3,583 |
| Gabapentin | 125 | $3,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $312 | $133,92778 claims |
| PfizerEliquis | $483 | $118,908105 claims |
| Lilly USA, LLCMounjaro, Trulicity | $109 | $103,98463 claims |
| Johnson & JohnsonXarelto | $21 | $40,43838 claims |
| Boehringer IngelheimJardiance | $67 | $39,01224 claims |
| GSKTrelegy Ellipta | $206 | $33,15227 claims |
| AstraZenecaFarxiga | $417 | $23,99616 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $22,57317 claims |
| AbbVieSynthroid | $75 | $2,01233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Centennial
- Joel ShebowichCentennial$32K
- Jill SchofieldCentennial$10K
- Stanton ElziWheat Ridge$9.2M
- Jason HenryDenver$7.3M
- Kenneth CohenLakewood$4.5M
- Luke WebbColorado Springs$2.1M
- Alexis LealAurora$2M
- Mauricio WaintrubAurora$1.3M
- Steven BrodieColorado Springs$883K
- Monica GrafalsAvon$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.